[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tourette-syndrome-in-adolescence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tourette-syndrome-in-adolescence":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,82,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100482172","neurofeedback-from-the-supplementary-motor-area-for-tourette-syndrome-100482172",false,"NCT05558566","Neurofeedback From the Supplementary Motor Area for Tourette Syndrome","Inclusion Criteria:\n\n* Boys and girls, 10 to 16 years of age\n* A current diagnosis of Tourette Syndrome (TS) or chronic tic disorder (CTD), with active tics that can be executed without head movement, and a YGTSS score of at least 13 (for TS participants) or at least 12 (for CTD participants)\n* Currently stable medication treatment and no planned changes in medication for the duration of the study.\n* Family residence within 2 hours of Yale Medical Center with ability and willingness to attend assessment and fMRI visits.\n* Children and their parents are expected to be able to speak and understand spoken English in order to participate in a clinical assessment of TS and related psychopathology.\n* Subjects will be free of: 1) metal medical implants or braces, 2) pregnancy, and will have 3) a body weight of less than 250 lbs. and 4) no claustrophobia.\n\nExclusion Criteria:\n\n* Intelligence quotient below 80\n* Current diagnosis of autism spectrum disorder, bipolar or psychotic disorder or current suicidality\n* Significant medical condition such as heart disease, hypertension, liver or renal failure, pulmonary disease, seizure disorder\n* Recently initiated psychotherapy. Participation in the study will not be allowed within 8 weeks of the initiation of psychotherapy. Ongoing, concurrent psychotherapy (that was initiated at least 8 weeks previously) for the child will be allowed, but parents will be asked not to initiate any new psychotherapy for the child during the study\n* Subjects may also be excluded after the first MR scan if we are unable to localize the two regions in their brain that are used as targets for the active and control neurofeedback conditions.","ALL","10 Years","16 Years",{"count":19,"type":20},64,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a clinical trial where adolescents aged 10-16 years old with Tourette Syndrome (or chronic tic disorder) are randomized to receive either real-time functional magnetic resonance imaging (fMRI) neurofeedback targeting the supplementary motor area (for the experimental intervention) or real-time fMRI neurofeedback (NF) from a control region (for the control intervention).",[26],"Tourette Syndrome in Adolescence","RECRUITING","2026-06-08",{"date":30,"type":31},"2026-06-09","ACTUAL",{"date":33,"type":31},"2022-11-01",{"date":35,"type":20},"2027-01-20",{"name":37,"class":38},"Yale University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100522340","phase-2-sertraline-vs-placebo-in-the-treatment-of-anxiety-in-children-and-adolescents-with-neurodevelopmental-disorders-100522340","NCT06081348","Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders","A Randomized Placebo-Controlled Trial of Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders","CALM","Inclusion Criteria:\n\n1. Outpatients 8-17 years of age, inclusive\n2. Females of child bearing potential who are sexually active and agree to use medically acceptable birth control throughout the study and at least one week post last dose of study drug.\n3. Meet Diagnostic and Statistical Manual of Mental Disorders - DSM-5 criteria for ASD, ADHD, Tic Disorders, or genetic diagnosis of Fragile X, tuberous sclerosis or 22q11 deletions.\n4. Meet DSM-5 criteria for one of the following anxiety disorders: Separation Anxiety Disorder, Social Anxiety Disorder, Agoraphobia, Generalized Anxiety Disorder, or Unspecified Anxiety Disorder, based on expert clinical interview, supported by the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS; Kaufman et al., 2016). Other specified anxiety disorder is included to account for youth with impairing anxiety symptoms who may not meet criteria for one of the other anxiety disorders.\n5. Have a Clinician's Global Impression-Severity for anxiety (CGI-S; Guy, 1976)) score ≥ 4 (moderately ill) (inter-rater reliability will be done prior to initiation of enrollment, using videotapes of interviews and vignettes)\n6. Have at least phrase speech, to allow for some self-report. So that results can be generalized to children and youth with NDD and various levels of ability, no IQ cut-off will be employed. Full-scale IQ (as measured by the Stanford-Binet) is measured to explore its effect on efficacy and safety\\*\n7. If already receiving interventions, must meet the following criteria:\n\n   1. If receiving concomitant medications affecting behaviour, must be on a stable dose during the month prior to screening and will not electively modify ongoing medications for study duration\n   2. If already receiving stable non-pharmacological behavioural interventions, have stable participation during 3 months prior to screening, and will not electively modify ongoing interventions\n8. Ability to complete assessments in English\u002FFrench\n\nExclusion Criteria:\n\n1. Receiving other SSRIs within four weeks of randomization (6 weeks for fluoxetine)\n2. Previous treatment with sertraline, at an adequate dose (at least 100mg for 6 weeks, or lower dose and duration if not well-tolerated), associated with no response or significant-to-the-participant side effects.\n3. Received more than 2 previous appropriate trials of SSRIs with no adequate response\n4. Pregnant females or sexually active females on inadequate contraception\n5. Serious medical condition that, based on Investigator judgment, might interfere with the conduct of the study, confound interpretation of the study results, or endanger participant. In addition diabetic patients on medications for glycemic control will be excluded as sertraline may interfere with glycemic control.\n6. Hypersensitivity to sertraline or any components of its formulation\n7. On Monoamine Oxidase Inhibitors or pimozide (as per product monograph)\n8. On concomitant medications known to significantly increase QT interval where this would result in unacceptable risk per Investigator judgment.\n9. Known congenital QT prolongation\n10. HIV, hepatitis B or C, hemophilia, abnormal blood pressure, substance abuse, immunity disorder, major depressive episode or psychosis (as required by Health Canada)\n11. Unable to tolerate venipuncture\n12. Unable to swallow capsules\n13. Enrolled in another intervention study","8 Years","17 Years",{"count":51,"type":20},130,[53],"PHASE2","There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs. More research is needed to confirm whether or not sertraline could help improve anxiety in children and youth with common and rare neurodevelopmental conditions. This is a pilot study, in which we plan to estimate the effect size of reduction in anxiety of sertraline vs. placebo. across rare and common neurodevelopmental disorders, and determine the best measure(s) to be used as a primary transdiagnostic outcome measure of anxiety, as well as diagnosis specific measures in future, larger-scale clinical trials of anxiety in NDDs.",[56,57,58,59,60,61,62,63,64,65,66,26,67,68,69,70,71],"Neurodevelopmental Disorders","Autism","Autism Spectrum Disorder","Fragile X Syndrome","Tuberous Sclerosis","22Q11 Deletion Syndrome","22Q11 Deletion","ADHD","Tic Disorders","Tourette Syndrome","Tourette Syndrome in Children","ADHD - Combined Type","ADHD Predominantly Inattentive Type","ADHD, Predominantly Hyperactive - Impulsive","Anxiety","Anxiety Disorders","2025-07-14",{"date":74,"type":31},"2025-07-16",{"date":76,"type":31},"2024-09-16",{"date":78,"type":20},"2026-09",{"name":80,"class":38},"Holland Bloorview Kids Rehabilitation Hospital",8,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":15,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":39},"100583247","cognitive-psychophysiological-treatment-for-tics-in-young-people-with-tourettes-syndrome-with-or-without-biofeedback-100583247","NCT06873841","Cognitive-psychophysiological Treatment for Tics in Young People With Tourette's Syndrome With or Without Biofeedback","Can the Cognitive-Psychophysiological Treatment of Tics be Optimized Through Biofeedback in Adolescents and Emerging Adults With Tourette Syndrome? - A Randomized Clinical Trial","CoBRa","Inclusion Criteria:\n\n* Have a diagnosis of TS or to experience bothersome tics;\n* Be aged 14 to 21 years inclusive at the start of therapy.\n\nExclusion Criteria:\n\n* Present a sensorimotor impairment;\n* Have a diagnosis of intellectual disability (intelligence quotient below 75);\n* Alcohol or drug abuse;\n* A neurological issue (e.g., hemifacial spasms, Huntington's disease);\n* Change medication one month or less before step 1 and up to step 4 (last measurement time) without informing a member of the research team;\n* Simultaneously receive another intervention for tics (e.g., psychologist, massage therapist) without informing a research team member.","14 Years","21 Years",{"count":93,"type":20},150,[23],"The goal of this clinical trial is to compare the effectiveness of CoPs therapy with or without the therapeutic component of biofeedback in treating tics in Tourette Syndrome with emerging young adults.\n\nHypotheses:\n\n1. The CoPs+Biofeedback treatment will improve the severity of tics (YGTSS) and the Clinical Global Impression, surpassing the clinical significance threshold of CoPs treatment alone.\n2. We expect that the identified variables (psychosocial, neurocognitive, biological) will predict the improvement of tics.\n\nResearchers will compare if the biofeedback treatment will improve the severity of tics.\n\n* In the pre-test, participants will undergo two interviews, each lasting 3 hours. These interviews will assess (through a battery of tests) the severity of tics as well as the psychosocial, biological, and neurocognitive aspects of functioning. A general assessment of intelligence and executive functions will also be conducted.\n* They will next attend 10 to 12 therapy sessions, with or without biofeedback. (The biofeedback component is explained in more detail in the ''Study Design'' section).\n* The post-test follow-ups consist of two evaluations: one 3 months after the end of the treatment and the other 6 months after. The evaluation will be done using the same battery of tests as during the pre-test interview.",[65,97,26],"Tics",[99,100,101,102,103,97,104],"CoPs","Biofeedback","cognitive-psychophysiological therapy","Tourette","Young adults","Treatment","2025-07-04",{"date":107,"type":31},"2025-07-08",{"date":109,"type":31},"2025-04-15",{"date":111,"type":20},"2029-12",{"name":113,"class":38},"Université du Québec a Montréal",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":49,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":39},"100579532","investigating-changes-in-premonitory-urges-during-habit-reversal-training-for-tics-100579532","NCT06825520","Investigating Changes in Premonitory Urges During Habit Reversal Training for Tics","Investigating Changes in Premonitory Urges During Habit Reversal Training","Inclusion Criteria:\n\nParticipants who meet criteria for a DSM-5-TR diagnosis of a TD will be recruited to participate in this study. Participants will be eligible for the study if they\n\n1. present with at least three motor and\u002For vocal tics and are interested in receiving treatment,\n2. report experiencing a PU for each of their target tics with a minimum rating of a 4\u002F8 on a subjective rating (i.e., the Urge Thermometer; Silverman \\& Albano, 1996) for each tic,\n3. the targeted tics occur, on average, at least once per minute during a 10-minute direct observation,\n4. are between the ages of 8 and 17\n5. the patient has no planned changes in medication initiation or dosage during their study participation period.\n\nExclusion Criteria:\n\n1. the presence of any comorbid conditions that are considered a primary treatment concern and\u002For could interfere with study participation or treatment (i.e., unmanaged ADHD, OCD, anxiety),\n2. have previously engaged in CBIT or HRT for more than 2 sessions,\n3. a Yale Global Tic Severity Score of 40+ (or 20+ if they present with a primary motor or vocal tic disorder),\n4. suspected (based on clinical presentation) that the tics are better attributed to functional neurological symptom disorder per DSM-5-TR criteria (APA, 2022).",{"count":122,"type":20},6,[23],"The primary aim of this study is to learn more about premonitory urges (PU) when using Habit Reversal Training (HRT) to treat tics.\n\nThe main focus of this study is to investigate if and when PU change during tic treatment sessions and between tic treatment sessions.\n\nParticipants will:\n\n* Attend 5 study visits (approximately 1 to 1.5 hours each) for an intake, habit reversal training for 3 separate tics, and a post assessment\n* Attend 5 practice sessions (approximately 30 minutes each) over a week for 3 weeks (total 15 practice sessions)\n* Study visits and practice sessions will take place in person and online via secure videoconference",[97,126,66,26],"Tourette Disorder",[128,129,130,131,132,133],"habit reversal training","tics","tourette","tourette's disorder","Tourette syndrome","treatment for tics","2025-05-21",{"date":136,"type":31},"2025-05-28",{"date":138,"type":31},"2025-02-11",{"date":140,"type":20},"2026-05",{"name":142,"class":38},"University of Utah"]